JESSICA OTIS: Open Payments
NPI 1255004727 · BATH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$757 in 22 payments from 10 companies in 2025. Trend: 2023 $599 · 2024 $612 · 2025 $757
Food & beverage: $757
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $329 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $157 |
| Exact Sciences Corporation | 3 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $58 |
| ABBVIE INC. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Abbott Laboratories | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: AIRSUPRA, CAPLYTA, Cologuard Collection Kit, JARDIANCE, Qelbree, VRAYLAR, INGREZZA, UBRELVY.
Industry payments across NY — which companies pay providers there.
